Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treating Patients With Melanoma and ALK Alterations With Ensartinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03420508
Recruitment Status : Recruiting
First Posted : February 2, 2018
Last Update Posted : January 4, 2019
Sponsor:
Collaborator:
Xcovery Holding Company, LLC
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma with a particular type of abnormality.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Ensartinib Diagnostic Test: ALKATI by Customized Nanostring Assay Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This single arm, single center, open label Phase 2 trial will utilize a Simon 2 stage design.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Actual Study Start Date : January 10, 2018
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: ensartinib
The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
Drug: Ensartinib
Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.

Diagnostic Test: ALKATI by Customized Nanostring Assay
a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI




Primary Outcome Measures :
  1. clinical benefit rate (CBR) [ Time Frame: up to 24 weeks ]
    CBR is defined as any confirmed objective response by Response Evaluation in Solid Tumor (RECIST) 1.1, or stable disease until the 24 week assessment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

For Screening Phase:

  • Patients ≥18 years of age
  • Histologically confirmed advanced malignant melanoma, regardless of subtype

For Treatment Phase, as above and in addition:

  • Progression following PD-1 based checkpoint inhibitor therapy, with or without ipilimumab. Tumors harboring BRAF V600 alterations must also have received prior therapy with BRAF inhibitors (with or without a MEK inhibitor). Patients with uveal melanoma are exempt from PD-1 based progression since there is no accepted standard frontline therapy.
  • Tumors must harbor an alteration in ALK using a CLIA-certified laboratory, including, but not limited to, ALKATI, ALK fusions, or ALK mutations.
  • Disease must be measurable according to RECIST 1.1. Disease that has undergone local therapy in the past 30 days is not considered measurable unless the investigator has documented progression despite the local therapy.

    ° If a patient has consented to the pre-screening portion, has been determined to have ALK alterations, but has no measurable disease, the trial may be favored later, and the patient should be consented (or re-consented) to the treatment portion of the trial at the discretion of the investigator.

  • Asymptomatic untreated brain metastases are allowed. Symptomatic metastases that have undergone local therapy with RT or surgery and have not required an increase in steroid dose in prior 2 weeks are allowed. Disease that has undergone local therapy is not considered measurable.
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2
  • Acceptable liver, renal, and hematological function:

    • total bilirubin ≤1.5x upper limit of normal (ULN); patients with Gilbert's Syndrome must have bilirubin ≤3x ULN
    • Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤3 x ULN (≤5x if liver metastases are present)
    • Estimated glomerular filtration rate (GFR) ≥ 30 mL/min using a cancer-specific GFR Model; the calculator found at: http://tavarelab.cruk.cam.ac.uk/JanowitzWilliamsGFR/
    • Hemoglobin ≥9 g/dL
    • Neutrophils ≥1.5 x 10^9/L
    • Platelets ≥100 x 10^9/L
    • Prothrombin time, international normalized ratio [INR], and/or activated partial thromboplastin time within ≤1.5 x ULN
  • Prothrombin time, international normalized ratio [INR], and/or activated partial thromboplastin time within ≤1.5 x ULN

Exclusion Criteria:

For Screening Phase:

  • Any prior ALK inhibition.

For Treatment Phase, as above and in addition:

Prior therapy with immune-activating agents within less than 1 cycle length prior to first day of study treatment (e.g. 3 weeks for ipilimumab or pembrolizumab; 2 weeks for nivolumab).

  • Prior therapy with BRAF/MEK agents within 3 weeks prior to first day of study treatment.
  • Any other systemic or regional anticancer therapy (cytotoxic chemotherapy, embolization) within 3 weeks or 1 cycle length, whichever is shorter, prior to first day of study treatment
  • Prior RT or clinically relevant major surgery (e.g. craniotomy, metastasectomy) within 2 weeks prior to first day of study treatment.
  • Any other active malignancy other than melanoma that, in the opinion of the investigator, would interfere with study participation.
  • Receipt of any other systemic anticancer therapy except for hormonal therapy for a hormonally sensitive (e.g. breast or prostate) cancer.
  • Receipt of strong CYP3A inhibitors or inducers per Appendix A.
  • Clinically significant cardiovascular disease, including:

    • QTc interval by Bazett's formula >480 ms
    • Symptomatic bradycardia <45 beats per minute
    • Other clinically significant ECG abnormalities (e.g. bundle branch block) may be eligible after discussion with the Principal Investigator
    • Clinically uncontrolled hypertension in the investigator's opinion.
  • The following within 6 months prior to Cycle 1 Day 1:

    • Congestive heart failure (New York Heart Class III or IV).
    • Cardiomyopathy.
    • o Arrhythmia or conduction abnormality requiring medication. Note: patients with atrial fibrillation/flutter adequately controlled by medication in the opinion of the treating physician and arrhythmias controlled by pacemakers are eligible.
    • Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction.
    • Cerebrovascular accident or transient ischemia.
  • Any serious, active infection at the time of treatment such as bacteremia
  • Interstitial lung disease or pneumonitis that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity. Patients with prior pneumonitis that has resolved are eligible.
  • Patients must not be pregnant or breast feeding, or unable or unwilling to use proper contraception during the study and up to 3 months following study completion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03420508


Contacts
Layout table for location contacts
Contact: Alexander Shoushtari, MD 646-888-4161 shoushta@mskcc.org
Contact: Paul Chapman, MD 646-888-4162

Locations
Layout table for location information
United States, New Jersey
Memoral Sloan Kettering Monmouth Recruiting
Middletown, New Jersey, United States, 07748
Contact: Alexander Shoushtari, MD    646-888-4161      
Memorial Sloan Kettering Bergen Recruiting
Montvale, New Jersey, United States, 07645
Contact: Alexander Shoushtari, MD    646-888-4161      
United States, New York
Memorial Sloan Kettering Westchester Recruiting
Harrison, New York, United States, 10604
Contact: Alexander Shoushtari, MD    646-888-4161      
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Alexander Shoushtari, MD    646-888-4161      
Contact: Paul Chapman, MD    646-888-4162      
Principal Investigator: Alexander Shoushtari, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Xcovery Holding Company, LLC
Investigators
Layout table for investigator information
Principal Investigator: Alexander Shoushtari Memorial Sloan Kettering Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03420508     History of Changes
Other Study ID Numbers: 17-471
First Posted: February 2, 2018    Key Record Dates
Last Update Posted: January 4, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center:
Ensartinib
ALK Inhibitor
ALK Alterations
Aberrant ALK Expression
17-471
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Ensartinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action